WOONSOCKET, RI , June 13, 2019 /CNW/ - Abacus Health Products ("Abacus" or the "Company") (ABCS.CN) CEO Perry Antelman will be a panel participant at the inaugural Institutional Capital & Cannabis Conference Europe (IC3 Europe ) to be held in London, England , on June 26, 2019 . The panel session, "The Path to Public Markets", will offer insights on the journeys of public companies in North America .
IC3 Europe will be a one-of-a-kind forum for investors who wish to learn more about this exciting and high-growth new asset class, as well as cannabis companies and investment funds looking to raise money or showcase their products.
Abacus is pleased to be a Patron Sponsor of this first annual event.
For more information about IC3 Europe , visit: https://www.imn.org/real-estate/conference/IC3-Institutional-Capital-Cannabis-Europe/
About Abacus Health Products, Inc.
Abacus is a company engaged in the development and commercialization of over-the-counter (OTC) registered topical medications with active pharmaceutical ingredients and which contain organic and natural ingredients, including a cannabinoid-rich hemp extract containing CBD from Cannabis sativa L plant. Abacus' products are aimed at the rapidly growing markets for topical pain relief and therapeutic skincare and are based on proprietary patent-pending technologies developed by Abacus. Abacus' formulations combine advanced science with organic and natural ingredients to provide safe relief. Abacus currently offers two lines of products: (i) CBD CLINIC™, marketed to the professional practitioner market, and (ii) CBDMEDIC™, marketed to the consumer market. Abacus' products are offered across the United States and are produced by a contract manufacturer in a cGMP compliant and audited manufacturing facility.
To learn more about Abacus, visit www.abacushp.com.
SOURCE Abacus Health Products
View original content to download multimedia: http://www.newswire.ca/en/releases/archive/June2019/13/c7188.html